Represents reimbursable costs incurred and recorded as deferred revenue on the condensed consolidated balance sheet.

No definition available.

Name:	incy_DeferredReimbursableCost
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementAmountRecognizedAndReceivedForAchievementOfPredefinedMilestone
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of deliverables under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementNumberOfDeliverables
Namespace Prefix:	incy_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents reimbursable costs pertaining to license agreements.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementReimbursableCosts
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents reimbursed costs pertaining to research and development expenses.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementResearchAndDevelopmentReimbursedCost
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront and immediate milestone payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentAndImmediateMilestonePaymentToBeReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the upfront payment received under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_LicenseAgreementUpfrontPaymentReceived
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of associated future global development costs from the initiation of a Phase IIb trial provided the entity elects to co-develop any compounds and/or indications.

+ References

No definition available.

+ Details

Name:	incy_PercentageFundingOnCostOnPossibleElectionOfCodevelopmentOfCompounds
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized.

+ References

No definition available.

+ Details

Name:	incy_PercentageOfRoyaltyRatePayments
Namespace Prefix:	incy_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty payment receivable under the license agreement.

+ References

No definition available.

+ Details

Name:	incy_RoyaltyPaymentReceivable
Namespace Prefix:	incy_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.

+ References

+ Details

Name:	us-gaap_ContractsRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name:	us-gaap_IncreaseDecreaseInRoyaltiesPayable
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_NovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_PreSpecifiedEventsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=incy_JAKAFIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=us-gaap_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_JP
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=incy_EliLillyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseTwoAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	incy_PhasesOfArrangementsAxis=incy_PhaseTwoBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License agreements (Details) $ in Thousands	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended					67 Months Ended	68 Months Ended
License agreements (Details) $ in Thousands	Jul. 31, 2010	Dec. 31, 2009 USD ($) item	Nov. 30, 2009 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)
License agreements
Contract revenues				$ 3,214	$ 3,214	$ 31,429	$ 13,429
Product royalty revenues				17,364	12,340	33,037	22,166
Novartis
License agreements
Upfront and immediate milestone payment to be received under license agreement			$ 210,000
Product royalties in accounts receivable				17,300		17,300		$ 14,800					$ 17,300	$ 17,300
Reimbursable costs recorded as deferred revenue		$ 10,900
Reimbursable costs included in accounts receivable				500		500		300					500	500
Research and development expenses reimbursed				500	1,100	1,000	2,200
Contract revenues				0	0	25,000	7,000
Novartis \| UNITED STATES
License agreements
Royalties payable				5,600		8,100
Novartis \| Pre-specified Events \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			1,200,000
Novartis \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone														97,000
Novartis \| Development Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			174,000
Novartis \| Regulatory Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone														$ 160,000
Novartis \| Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			495,000
Novartis \| Commercialization Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement			$ 500,000
Novartis \| JAKAFI
License agreements
Product royalty revenues				17,400	12,300	33,000	22,200
Novartis \| JAKAFI \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone								7,000	$ 25,000		$ 15,000
Novartis \| JAKAFI \| Regulatory Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone											$ 10,000
Novartis \| JAKAFI \| Regulatory Milestones \| Europe
License agreements
Amount recognized and received for the achievement of a predefined milestone						25,000		60,000		$ 40,000
Novartis \| JAKAFI \| Regulatory Milestones \| JAPAN
License agreements
Amount recognized and received for the achievement of a predefined milestone								$ 25,000
Eli Lilly
License agreements
Number of deliverables under license agreement \| item		2
Upfront payment received under license agreement		$ 90,000
Research and development expenses reimbursed				10,300	12,700	21,900	26,700
Contract revenues				$ 3,200	$ 6,400	$ 3,200	$ 6,400
Associated future global development costs from the initiation of a Phase IIb trial, if elected to co-develop, percentage	30.00%	30.00%		30.00%		30.00%
Eli Lilly \| Maximum
License agreements
Range of royalty payments on future global net sales (as a percent)						20.00%
Eli Lilly \| Pre-specified Events \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement		$ 665,000
Eli Lilly \| Development Milestones
License agreements
Amount recognized and received for the achievement of a predefined milestone													$ 99,000
Eli Lilly \| Development Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement		150,000
Eli Lilly \| Development Milestones \| Phase Three
License agreements
Amount recognized and received for the achievement of a predefined milestone										$ 50,000
Eli Lilly \| Development Milestones \| Phase Two A
License agreements
Amount recognized and received for the achievement of a predefined milestone												$ 30,000
Eli Lilly \| Development Milestones \| Phase Two B
License agreements
Amount recognized and received for the achievement of a predefined milestone												$ 19,000
Eli Lilly \| Regulatory Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement		365,000
Eli Lilly \| Commercialization Milestones \| Maximum
License agreements
Upfront and immediate milestone payment to be received under license agreement		$ 150,000